Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 11, 2005, Pages 582-589

  Zielińska, Elzbieta ^a   Zubowska, Małgorzata ^a   Misiura, Konrad ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

Author keywords

Children; Genotype GSTM1; GSTP1; GSTT1; Ifosfamide; Nephrotoxicity; Neurotoxicity; Side chain metabolism

Indexed keywords

2 DECHLOROETHYLIFOSFAMIDE; 3 DECHLOROETHYLIFOSFAMIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN; CARBOPLATIN; CISPLATIN; CREATININE; CYTOSTATIC AGENT; DACTINOMYCIN; DRUG METABOLITE; EPIRUBICIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; IFOSFAMIDE; METHOTREXATE; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DETOXIFICATION; DRUG EXCRETION; DRUG INFUSION; DRUG METABOLISM; FEMALE; GENE IDENTIFICATION; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NEUROTOXICITY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RANK SUM TEST; THEORETICAL MODEL; TOXICITY; URINARY EXCRETION;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; IFOSFAMIDE; INFANT; KIDNEY DISEASES; LEUKEMIA; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROTOXICITY SYNDROMES; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 28144457187     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000187429.52616.8a     Document Type: Article

References (44)

1. Carli M, Passone E, Perilongo G, et al. Ifosfamide in pediatric solid tumors. Oncology. 2003;65(suppl 2):99-104.
2. Pratt CB. Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia. Semin Oncol. 1990;17:31-40.
3. Klastersky J. Side effects of ifosfamide. Oncology. 2003;65(suppl 2): 7-10.
4. Lee BS, Lee JH, Kang HG, et al. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr Nephrol. 2001;16:796-799.
5. Raney B, Ensing LG, Foreman J, et al. Renal toxicity of ifosfamide in pilot regimens of the Intergroup Rhabdomyosarcoma Study for patients with gross residual tumor. Am J Pediatr Hematol Oncol. 1994;16:286-295.
6. Skinner R, Cotterill SJ, Stevens MCG. United Kingdom Children's Cancer Study Group Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG late effects group study. Br J Cancer. 2000;82: 1636-1645.
7. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol. 2003;41:190-197.
8. Zielińska E, Bodalski J. Growth retardation and osteomalacia as a result of ifosfamide nephrotoxicity in 3-year-old boy whose genotype reveal the genes encoding glutathione S-transferases GSTM1 and GSTT1. Cytobios. 2001;106:193-201.
9. Meyer T, Ludolph AC, Munch C. Ifosfamide encephalopathy presenting with asterixis. J Neurol Sci. 2002;99:85-88.
10. Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology. 2003;65(suppl 2):11-16.
11. Orbach D, Brisse H, Doz F. Central neurological manifestations during chemotherapy in children. Arch Pediatr. 2003;10:533-539.
12. Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82:291-294.
13. Primavera A, Audenino D, Cocito L. Ifosfamide encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci. 2002;29:180-183.
14. Rieger C, Fiegl M, Tischer J, et al. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs. 2004;15:347-350.
15. Shuper A, Stein J, Goshen J, et al. Subacute central nervous system degeneration in a child: an unusual manifestation of ifosfamide intoxication. J Child Neurol. 2000;15:481-483.
16. Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet. 2001;40:41-62.
17. 31P NMR spectroscopy. Arzneim Forsch Drug Res. 2003;53:372-377.
18. Silies H, Blaschke G, Hohenlöchter B, et al. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion. Int J Clin Pharmacol Ther. 1998;36:246-252.
19. Kaijser GP, Keizer HJ, Beijnen JH, et al. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion. Anticancer Res. 1996;16:3247-3257.
20. Lind MJ, McGown AT, Hadfield JA, et al. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol. 1989;38:1835-1840.
21. Sood C, O'Brien PJ. 2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity. Br J Cancer. 1996;27:S287-S293.
22. Zaki EL, Springate JE, Taub M. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. Toxicol In Vitro. 2003;17:397-402.
23. Dirven HA, Megens L, Oudshoorn MJ, et al. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem Res Toxicol. 1995;8:979-986.
24. Mannervik B, Wildersten M. Human glutathione transferases: classification, tissue distribution, structure, and functional properties. In: Pacifici GM, Fracchia GN, eds. Advances in Drug Metabolism in Man. European Commission ECSC-EC-EAEC, Brussels, 1995:408-459.
25. Lin HJ, Han Ch-Y, Bernstein DA, et al. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis. 1994;15:1077-1081.
26. Nelson HH, Wiencke JK, Christiani DC, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis. 1995;16:1243-1245.
27. Coughlin SS, Hall IJ. Glutathione S-transferase polymorphisms and risk of ovarian cancer: a HuGE review. Genet Med. 2002;4:250-257.
28. Misiura K, Okruszek A, Pankiewicz K, et al. Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine. J Med Chem. 1983;26:674-679.
29. Zhong S, Howie AF, Ketterer B, et al. Glutathione S-transferase μ locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis. 1991;12:1533-1537.
30. Pemble S, Schroeder KR, Spencer SS, et al. Human glutathione S-transferase (GSTT1): cDNA cloning and the characterisation of a genetic polymorphism. Biochem J. 1994;300:271-276.
31. Harries LW, Stubbins MJ, Forman D, et al. Identification of genetic polymorphisms at the glutathione S-transferase pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 1997;18:641-644.
32. Zielińska E, Zubowska M, Bodalski J. Polymorphism within the glutathione S-transferase P1 gene is associated with increased susceptibility to childhood malignant diseases. Pediatr Blood Cancer. 2004;43:552-556.
33. Hartmann JT, Fels LM, Knop S, et al. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs. 2000;8:281-289.
34. Aleksa K, Woodland C, Koren G. Young age and the risk for ifosfamide induced nephrotoxicity: a critical review of two opposing studies. Pediatr Nephrol. 2001;16:1153-1158.
35. 31P nuclear magnetic resonance spectroscopy. J Pharmacol Exp Ther. 1992;260:1133-1144.
36. Roy P, Yu LJ, Crespi CL, et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999;27:655-666.
37. Ishimoto TM, Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics. 2002;12:543-553.
38. Srivastava SK, Singhal SS, Hu X, et al. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys. 1999;366:89-94.
39. Sundberg K, Johansson AS, Stenberg G, et al. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocorbons. Carcinogenesis. 1998;19:433-436.
40. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res. 2000;463:247-283.
41. Juronen E, Tasa G, Uuskula M, et al. Purification, characterization and tissue distribution of human class theta glutathione S-transferase T1-1. Biochem Mol Biol Int. 1996;39:21-29.
42. Kaijser GP, De Kraker J, Bult A, et al. Pharmacokinetics of ifosfamide and some metabolites in children. Anticancer Res. 1998;18:1941-1949.
43. Woodland C, Ito S, Granvil CP, et al. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci. 2000;68:109-117.
44. Westlind A, Löfberg L, Tindberg N, et al. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun. 1999;259:201-205.